Patents by Inventor Stuart Tugendreich
Stuart Tugendreich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7778782Abstract: The present invention includes methods and apparatus for use in rapid testing for and prediction of a PPAR? response (i.e. a response similar to that of PPAR? agonists). The invention includes a PPAR? response signature comprising a set of twenty genes. The invention discloses methods whereby the differential expression of the genes of the PPAR? response signature may be used to predict whether a compound will induce a PPAR? response in a test subject.Type: GrantFiled: December 16, 2003Date of Patent: August 17, 2010Assignee: Entelos, Inc.Inventors: Cecelia Pearson, Michael Furness, Stuart Tugendreich, Georges Natsoulis
-
Patent number: 7422854Abstract: The present invention provides methods and compositions for use in rapid test or prediction of the propensity of a test compound to induce cholesterol reduction in a subject. The invention also includes a cholesterol reduction signature as well as the method of deriving such signature.Type: GrantFiled: December 18, 2003Date of Patent: September 9, 2008Assignee: Entelos, Inc.Inventors: Georges Natsoulis, Stuart Tugendreich, Cecelia Pearson, Michael Furness
-
Patent number: 7396645Abstract: The present invention provides methods and compositions for use in rapid test or prediction of the propensity of a test compound to induce cholestasis in a subject. The invention also includes a Cholestasis signature database as well as the method of deriving such database.Type: GrantFiled: December 16, 2003Date of Patent: July 8, 2008Assignee: Entelos, Inc.Inventors: Georges Natsoulis, Cecelia Pearson, Stuart Tugendreich, Michael Furness
-
Patent number: 7053216Abstract: Compounds of formula 1 modulate the activity of Rho C: wherein R1 is H, lower alkyl, aralkyl, aryl-lower alkenyl, or —(CH2)nCH(R7)NR8R9, where n is 0–6 inclusive, R7 is H, lower alkyl, aryl, or aralkyl, R8 is H, lower alkyl, cyclo-alkyl, aryl, or aralkyl, and R9 is R, RCO—, ROCO—, or RNHCO—, where R is lower alkyl, cycloalkyl, aryl, or aralkyl, wherein aryl and aralkyl are substituted with 0–3 substituents selected from the group consisting of lower alkyl, halo, nitro, —OH, trifluoromethyl, or lower alkoxy; R2 is lower alkyl, aryl, aralkyl, or —(CHR10)m—(CO)—R11, wherein m is 0–4, R10 is H or lower alkyl, and R11 is lower alkyl, cycloalkyl, aryl, or aralkyl, wherein aryl and aralkyl are substituted with 0–3 substituents selected from the group consisting of lower alkyl, halo, nitro, —OH, trifluoromethyl, or lower alkoxy; R3, R4, R5, and R6, are each independently H, lower alkyl, halo, nitro, OH, lower alkoxy, NH2, lower alkylamino, di(lower alkylamino), trifluoromethyl, or SH; or a pharmaceutically acceType: GrantFiled: November 19, 2002Date of Patent: May 30, 2006Assignee: Iconix Pharmaceuticals, Inc.Inventors: Dongxu Sun, Edward L. Perkins, Stuart Tugendreich
-
Patent number: 7049468Abstract: Compounds of formula 1 modulate the activity of Rho C: wherein R is a direct bond, lower alkylene, —C(O)NH—, or —NHC(O)—; Ar is aryl or heteroaryl, substituted with R7, R8, R9, and R10, wherein R7, R8, and R9 are each independently H, halo, lower alkyl, OH, lower alkoxy, and R10 is H, halo, lower alkyl, OH, lower alkoxy, or forms a ring with R1; R1 is H, lower alkyl, or forms a ring with R10; R2, R3, R4, R5, and R6 are each independently H, lower alkyl, halo, nitro, OH, lower alkoxy, NH2, lower alkylamino, di(lower alkyl)amino, or two adjacent groups together form a saturated or unsaturated ring; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 19, 2002Date of Patent: May 23, 2006Assignee: Iconix Pharmaceuticals, Inc.Inventors: Dongxu Sun, Edward L. Perkins, Stuart Tugendreich
-
Publication number: 20040259764Abstract: Disclosed is a method for predicting the propensity of a compound to cause depletion of reticulocytes in a mammal.Type: ApplicationFiled: October 22, 2003Publication date: December 23, 2004Inventors: Stuart Tugendreich, Cecelia Pearson, Michael Furness, Georges Natsoulis
-
Patent number: 6800634Abstract: Compounds of formula 1 modulate the activity of Rho C: wherein R1 is H, OH, or lower alkyl; R2, R3, R4, R5, and R6 are each independently H, halo, lower alkyl, OH, lower alkoxy, NH2, lower alkylamino, di(lower alkyl)amino, SH, lower alkylthio, NO2, or two residues together form a heterocyclic ring; R7, R8, R9, and R10 are each independently H, lower alkyl, OH, NH2, aryl, or aralkyl, where aryl and aralkyl are substituted with 0-3 moieties selected from the group consisting of halo, OH, NH2, lower alkyl, lower alkoxy, SH, lower alkylthio, and lower alkylamino; R11, R12, R13, R14, R15, and R16 are each independently H, halo, lower alkyl, OH, lower alkoxy, or NO2; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 19, 2002Date of Patent: October 5, 2004Assignee: Iconix Pharmaceuticals Inc.Inventors: Dongxu Sun, Edward L. Perkins, Stuart Tugendreich
-
Patent number: 6653075Abstract: A method for identifying a mutation-sensitive active region of a test protein, by providing a test nucleic acid construct comprising a regulatable promoter polynucleotide and a fusion polynucleotide comprising a test polynucleotide encoding the test protein fused to a reporter gene, wherein said fusion polynucleotide is operably associated with the promoter polynucleotide, wherein expression of the fusion polynucleotide in a selected host cell results in a specific phenotype and the presence of the reporter; mutagenizing the test nucleic acid construct to provide a mutagenized construct; transforming a selected host cell with the mutagenized construct to provide a transformed host cell; selecting a transformed host cell that exhibits the reporter, but which does not exhibit the specific phenotype; and sequencing a portion of the mutagenized construct from the selected transformed host cell to determine the alteration of the polynucleotide(s).Type: GrantFiled: December 15, 2000Date of Patent: November 25, 2003Assignee: Iconix Pharmaceuticals, Inc.Inventors: Stuart Tugendreich, Fernando J. Rebelo Do Couto
-
Patent number: 6642263Abstract: Compounds of formula 1 modulate the activity of Rho C: wherein n is 2 to 5, inclusive; R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently H, halo, lower alkyl, lower alkoxy, lower alkylamino, trifluoromethyl, nitro, lower alkylthio, or two adjacent residues form cycloalkyl, cycloalkenyl, aryl, or lower alkylenedioxy; and pharmaceutically acceptable salts thereof.Type: GrantFiled: November 19, 2002Date of Patent: November 4, 2003Assignee: Iconix Pharmaceuticals Inc.Inventors: Dongxu Sun, Edward L. Perkins, Stuart Tugendreich, Ving J. Lee
-
Publication number: 20030176474Abstract: Compounds of formula 1 modulate the activity of Rho C: 1Type: ApplicationFiled: November 19, 2002Publication date: September 18, 2003Inventors: Dongxu Sun, Edward L. Perkins, Stuart Tugendreich, Ving J. Lee
-
Publication number: 20030171341Abstract: Compounds of formula 1 modulate the activity of Rho C: 1Type: ApplicationFiled: November 19, 2002Publication date: September 11, 2003Inventors: Dongxu Sun, Edward L. Perkins, Stuart Tugendreich
-
Publication number: 20030171390Abstract: Compounds of formula 1 modulate the activity of Rho C: 1Type: ApplicationFiled: November 19, 2002Publication date: September 11, 2003Inventors: Dongxu Sun, Edward L. Perkins, Stuart Tugendreich
-
Publication number: 20030171387Abstract: Compounds of formula 1 modulate the activity of Rho C: 1Type: ApplicationFiled: November 19, 2002Publication date: September 11, 2003Inventors: Dongxu Sun, Edward L. Perkins, Stuart Tugendreich
-
Publication number: 20020183393Abstract: Compounds of formula 1: 1Type: ApplicationFiled: September 14, 2001Publication date: December 5, 2002Inventors: David J. Morgans, Teri Melese, Stuart Tugendreich
-
Publication number: 20020009710Abstract: A method for identifying a mutation-sensitive active region of a test protein, by providing a test nucleic acid construct comprising a regulatable promoter polynucleotide and a fusion polynucleotide comprising a test polynucleotide encoding the test protein fused to a reporter gene, wherein said fusion polynucleotide is operably associated with the promoter polynucleotide, wherein expression of the fusion polynucleotide in a selected host cell results in a specific phenotype and the presence of the reporter; mutagenizing the test nucleic acid construct to provide a mutagenized construct; transforming a selected host cell with the mutagenized construct to provide a transformed host cell; selecting a transformed host cell that exhibits the reporter, but which does not exhibit the specific phenotype; and sequencing a portion of the mutagenized construct from the selected transformed host cell to determine the alteration of the polynucleotide(s).Type: ApplicationFiled: December 15, 2000Publication date: January 24, 2002Inventors: Stuart Tugendreich, Fernando J. Rebelo Do Couto
-
Publication number: 20020004197Abstract: Methods and nucleic acid constructs for testing and validating activity reporter cells, using a plurality of host cell genes, are described.Type: ApplicationFiled: August 28, 2001Publication date: January 10, 2002Applicant: Iconix Pharmaceuticals, Inc.Inventors: Teri Melese, Edward L. Perkins, Stuart Tugendreich
-
Publication number: 20010031461Abstract: A method for potentiating a host cell for sensitivity to a heterologous polynucleotide comprises providing a population of host cells, wherein the cells comprise a heterologous polynucleotide, a first promoter regulating the expression of the heterologous polynucleotide, and a replicable genetic element comprising a second polynucleotide encoding a repressor of the first promoter, a reporter gene under the control of a second promoter, expression of which provides a detectable label, and an origin of replication, wherein the replicable genetic element is subject to loss by the host cells, thus resulting in heterogeneously labeled colonies when the host cells are cultured; mutagenizing the population of host cells; growing colonies of the mutagenized host cells under conditions wherein the heterologous polynucleotide, the repressor, and the reporter are all expressed; and identifying a colony of mutagenized host cells that is homogeneously labeled.Type: ApplicationFiled: December 15, 2000Publication date: October 18, 2001Inventor: Stuart Tugendreich